Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is positioned to succeed due to its diversified healthcare portfolio, strong commercial strategy, and key system advantages in its various product categories. With a strong pipeline of new products and expansion into emerging markets, Abbott is poised to continue its growth in sales and EPS. The company also has a strong track record of capital deployment and cash generation, making it a compelling investment opportunity.

Bears say

Abbott Laboratories is experiencing strong growth in the EP market and the success of its Exact Sciences acquisition is expected to lead to further growth in the cancer diagnostics market. However, potential risks such as geopolitical tensions and unfavorable changes in healthcare regulations could impact profitability. The company's Nutritional Products segment has shown a decline in sales but management is implementing strategies to improve volume growth and launch new products. The company also faces risks related to patent and trademark protection and litigation. Despite some positive developments, the potential for negative impact on profitability from external factors warrants a negative outlook on Abbott's stock.

Abbott Labs (ABT) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 18 analysts, Abbott Labs (ABT) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.